{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:29:54Z","timestamp":1790022594017,"version":"4.0.1"},"reference-count":37,"publisher":"Consilium Medicum","issue":"2","license":[{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Aim.To study liver function and portal hypertension, incidence and risk factors of liver-related complications, including hepatocellular carcinoma (HCC), in patients with HCV-related liver cirrhosis achieved sustained virologic response (SVR) after direct-acting antiviral therapy.\r\nMaterials and methods.Patients with HCV-related liver cirrhosis were followed up after achievement SVR with assessment of liver function parameters, portal hypertension, Model for End-stage Liver Disease (MELD) and \u0421hild  Pugh (CP) scores, complications development, including HCC, every 36 months. The median follow-up duration was 24 [18; 30] months after end of treatment.\r\nResults.At last observation, a number of cirrhotic patients with CP class A increased from 72% to 85%, with CP class B reduced from 23.5% to 12.5%, with CP class C  from 4.5% to 2.5%. In 89% patients were identified a regress of liver fibrosis (from 23.5 [16.9; 28] to 15.0 [10.2; 21.3] kPa,p0.005), each third patient  reduction of fibrosis stage to F2\/F3. In 19 (9.5%) patients were occurred liver-related complications, including HCC (in 9 patients). Baseline high total bilirubin level (34 mol\/l) (Hazard ratio (HR) 11.5, 95% confidence interval (CI) 2.357.8,\u04400.005) and ascites (HR=17.6, 95% CI 2.1144.8,p=0.008) were independent risk factors associated with HCC development.\r\nConclusion.The risk of HCC development remains in patients with HCV-related liver cirrhosis, despite on eradication of hepatitis C virus. Therefore, these patients should continue to undergo more intensive examination (ultrasound examination and determination of alfa-fetoprotein level each 36 months), including contrast-enhanced methods of imaging, the frequency of which should be determined.<\/jats:p>","DOI":"10.26442\/00403660.2020.02.000511","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T14:35:20Z","timestamp":1593441320000},"page":"34-42","source":"Crossref","is-referenced-by-count":3,"title":["The long-term prospective study of patients with liver cirrhosis after elimination of the hepatitis C virus"],"prefix":"10.26442","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4534-7991","authenticated-orcid":false,"given":"E. A.","family":"Nabatchikova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. T.","family":"Abdurakhmanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. N.","family":"Nikulkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. P.","family":"Rozina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. L.","family":"Tanaschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. V.","family":"Nikiforova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. S.","family":"Adonyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. V.","family":"Moiseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18344","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"key":"ref1","unstructured":"Global Hepatitis Report 2017. Geneva: World Health Organization, 2017. ISBN 978-92-4-156545-5"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.20953\/1729-9225-2018-3-37-45"},{"key":"ref3","unstructured":"Blach S, Zeuzem S, Manns M, Altraif I, Duberg A, Muljono DH, et al. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161-76. doi: 10.1016\/ S2468-1253(16)30181-9"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.05.2013"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22375"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24370"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20562"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ860"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.144878"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.10.026"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21440"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23340"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.05.010"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27922"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.22416\/1382-4376-2017-27-6-52-62"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1512614"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.22416\/1382\u00ac4376\u00ac2017\u00ac27\u00ac4\u00ac41\u00ac51"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001250"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13629"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Mangia A, Lawitz E, Gane E, Conway B, Ruane P, Abergel A, Mcnabb B, et al. Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with sofosbuvir-based regimens. J Hepatol. 2018;68:S67-S68. doi: 10.1016\/ s0168-8278(18)30356-8","DOI":"10.1016\/S0168-8278(18)30356-8"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Sporea I, Lupusoru R, Mare R, Popescu A, Gheorghe L, Iacob S, Sirli R. Dynamics of liver stiffness values by means of transient elastography in patients with HCV liver cirrhosis undergoing interferon free treatment. J Gastrointestin Liver Dis. 2017;26(2):145-50. doi: 10.15403\/ jgld.2014.1121.262.dyn","DOI":"10.15403\/jgld.2014.1121.262.dyn"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12578"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14008"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.20953\/1729-9225-2016-4-37-43"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.07.015"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.10.033"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.04.008"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep2018.03.009"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.10.017"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27095"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology. 2007;46(5):1350-6. doi: 10.1002\/ hep.21826","DOI":"10.1002\/hep.21826"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.06.015"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.06.009"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28632"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.08.030"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14593"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29707"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/33898\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/33898\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T20:55:45Z","timestamp":1634158545000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/33898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,27]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2020.02.000511","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"value":"2309-5342","type":"electronic"},{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,27]]}}}